TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

Inclusion Criteria:

• Patients aged 18 years or older

• Histologically confirmed adenocarcinoma of the breast

• Assumed clinical or pathological stage III (TNM) breast cancer

• Breast tumor must be:

• HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 atimmunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH)

• Hormone receptor negative i.e. an estrogen receptor (ER) of <10% andprogesterone receptor (PR) of <10%.; or in case of a histological grade IIItumor an ER of <50% and a PR of <50%.

• Patients are planned to receive the complete standard of care in the Netherlands;neo-adjuvant chemotherapy according to local practise

• Participating patients have to be able to use a mobile phone, tablet, laptop and/orcomputer and understand the Dutch language

Exclusion Criteria:

• Evidence of distant metastases. Staging examinations should have been performedaccording to Dutch national guidelines.

• Patients who are only treated systemically in the adjuvant setting

• Participation in another clinical study with an treatment intervention during thecourse of this study.